menu
    • menu
    [{"orgOrder":0,"company":"Grey Wolf Therapeutics","sponsor":"Pfizer Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Series B Financing","leadProduct":"Cemiplimab","moa":"||ERAP1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Grey Wolf Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Grey Wolf Therapeutics \/ Pfizer Ventures","highestDevelopmentStatusID":"7","companyTruncated":"Grey Wolf Therapeutics \/ Pfizer Ventures"},{"orgOrder":0,"company":"Grey Wolf Therapeutics","sponsor":"ICG\u2019s Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Series B Financing","leadProduct":"GRWD5769","moa":"ERAP1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Grey Wolf Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Grey Wolf Therapeutics \/ ICG\u2019s Life Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Grey Wolf Therapeutics \/ ICG\u2019s Life Sciences"},{"orgOrder":0,"company":"Grey Wolf Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"||ERAP1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Grey Wolf Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Grey Wolf Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Grey Wolf Therapeutics \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Grey Wolf Therapeutics

    Menu

    Grey Wolf Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Grey Wolf Therapeutics

                            United Kingdom arrow
                            CRS
                            Not Confirmed

                            Grey Wolf Therapeutics

                            United Kingdom arrow
                            CRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GRWD5769

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : ICG’s Life Sciences

                            Deal Size : $99.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Grey Wolf Therapeutics Closes Oversubscribed $50 Million Series B

                            Details : The financing aims to fund the clinical development of GRWD5769 a first-in-class ERAP1 inhibitor, which is being evaluated for the treatment of neoplasms.

                            Product Name : GRWD5769

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            May 22, 2024

                            Lead Product(s) : GRWD5769

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : ICG’s Life Sciences

                            Deal Size : $99.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Grey Wolf Therapeutics

                            United Kingdom arrow
                            CRS
                            Not Confirmed

                            Grey Wolf Therapeutics

                            United Kingdom arrow
                            CRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GRWD5769,Cemiplimab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Grey Wolf Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of GRWD5769 in Patients w...

                            Details : GRWD5769 is the first-in-class ERAP1 inhibitor, being investigated as alone and in combination with libtayo for the treatment of advanced solid tumours.

                            Product Name : GRWD5769

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 28, 2023

                            Lead Product(s) : GRWD5769,Cemiplimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Grey Wolf Therapeutics

                            United Kingdom arrow
                            CRS
                            Not Confirmed

                            Grey Wolf Therapeutics

                            United Kingdom arrow
                            CRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GRWD5769,Cemiplimab

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Pfizer Ventures

                            Deal Size : $49.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Grey Wolf Therapeutics Closes Oversubscribed $49 Million Series B Financing to Advance First-of-its-Kind Neoan...

                            Details : Grey Wolf Therapeutics will use the net proceeds to Support Advancement of Lead Candidate, ERAP1 Inhibitor GRWD5769, into a Phase 1/2 clinical trial in the first half of 2023 and support the continued development of the company's first-of-its-kind immuno...

                            Product Name : GRWD5769

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 26, 2023

                            Lead Product(s) : GRWD5769,Cemiplimab

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Pfizer Ventures

                            Deal Size : $49.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth